Omthera Pharmaceuticals, which is developing therapies for abnormalities in blood lipids, filed on Monday with the SEC to raise up to $75 million in an initial public offering. The Princeton, NJ-based company, which was founded in 2008, currently does not produce any revenue from its drug candidates. It plans to list on the NASDAQ under the symbol OMTH. BofA Merrill Lynch, Barclays and Leerink Swann are the joint bookrunners on the deal. No pricing terms were disclosed.